BRAF mutated melanoma journey in Latin America:
Expert recommendations from diagnosis to treatment 

Melanoma prevalence in LATAM is lower than in high- and middle-income countries. However, recent data indicate that the region's incidence and mortality are rising, with more stage IV patients being diagnosed. According to international clinical practice guidelines, it is imperative to conduct BRAF-mutation testing in patients with stage III or stage IV melanoma and high-risk resected disease. Still, BRAF-mutation testing and targeted therapies are inconsistently available in the region.

In April 2023, AHF convened a meeting of Latin American experts on BRAF-mutated melanoma to develop guidelines and recommendations for diagnosis through treatment. The manuscript, entitled “BRAF mutated melanoma journey in Latin America: Expert recommendations from diagnosis to treatment”,  has been published in Cancer Control. You can access the publication here.

Lead author: María A. Bravo-Garzón.